PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF LY3202626, A NOVEL BACE1 INHIBITOR, IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER’S DISEASE